GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

SP2086

Company
Jiangsu HengRui Medicine Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01969318

    Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 120 participants Est. completion 2012-11 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01969357

    A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 200 participants Est. completion 2012-06 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01970033

    Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 450 participants Est. completion 2015-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01970046

    A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 360 participants Est. completion 2015-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02500485

    The Drug-drug Interaction of SHR3824 and SP2086

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 12 participants 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02813863

    The Drug-drug Interaction of SP2086 and Metformin

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02815657

    The Drug-drug Interaction of SP2086 and Valsartan

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 16 participants Est. completion 2014-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02815722

    The Drug-drug Interaction of SP2086 and Simvastatin

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 16 participants Est. completion 2014-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02815748

    The Metabolite Identification and Material Balance Study of SP2086

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 8 participants Est. completion 2015-10
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02815774

    SP2086 Pharmacokinetic Study in Renal Insufficiency Patients

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 30 participants Est. completion 2015-01
    Other conditions: Renal Insufficiency
    View official trial listing →
  • Completed NCT NCT02815787

    The Drug -Drug Interaction of SP2086 and Glyburide

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 16 participants Est. completion 2014-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02817217

    The DDI Study of SP2086 and Valsartan

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02817243

    The DDI Study of SP2086 and Simvastatin

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02821871

    the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2016-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02822534

    The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02826044

    The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 30 participants 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05682495

    A HR20031 BE Study on Healthy Subjects

    Not yet reported Shandong Suncadia Medicine Co., Ltd. 96 participants Est. completion 2023-04-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06035406

    A Trial of SP2086 With Hepatic Insufficiency

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2023-12
    Other conditions: Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.